Navigation Links
SemBioSys to present new data at American Diabetes Association,annual meeting

TSX symbol: SBS

CALGARY, June 20, 2007 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced that it will be presenting a scientific poster and abstract at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The Company's poster will disclose recent accomplishments in the development of a highly-scalable, low cost source of recombinant human insulin. Poster session presentations will take place at the McCormick Place Convention Center on Saturday June 23 from 6:00pm to 7:15 pm and on Monday June 25 from 12:00pm to 2:00pm. The poster and abstract are titled:

"Chemical and Biological Characterization of Recombinant Human Insulin Produced in Transgenic Plants." Abstract Number 0459-P by Joseph Boothe, Cory Nykiforuk, Elizabeth Murray, Philip Kuhlman, W. Brent Pollock, Amanda Bodero, Joseph Goren, Richard Keon, Nancy Markley, and Maurice Moloney.

About SemBioSys Genetics Inc. (www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing insulin and other protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead candidate is recombinant human insulin produced in the plant host safflower, to serve the rapidly expanding global diabetes market and to supply insulin for inhalation and other alternative insulin delivery technologies. The Company's other protein-based pharmaceutical candidate is a cardiovascular drug called Apo AI. SemBioSys is also developing a series of non-pharmaceutical products addressing animal and aquaculture health, nutritional oils and human topical markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

CONTACT: SemBioSys Genetics Inc., Mr. Andrew Baum, President and ChiefExecutive Officer, Phone: (403) 717-8767, Fax: (403) 250-3886, E-mail:, Internet: www.sembiosys.com; Investor Relations, RossMarshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:(416) 815-0080, E-mail: bauma@sembiosys.com rmarshall@equicomgroup.com

Ticker Symbol: (Toronto:SBS.)

Terms and conditions of use apply
Copyr ight © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
4. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
5. CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007
6. Data to be presented at AAN Meeting -Study results of drug candidate for MS
7. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
8. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
9. Data supporting three Antisoma programmes presented at AACR
10. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 Mosaic Life Care, based in ... patient registration process across its network of 58 clinics, located in 22 cities, and ... new and innovative ways to improve the delivery of health care to its patients, ... Reading ... Mosaic Life Care St. Joseph Medical Center ...
(Date:3/23/2017)... 2017  Transportation Insight, a multi-modal lead logistics solutions ... management firm with expertise serving clients in the food ... Zaffarano was named a 2017 Food Logistics ... the only publication exclusively dedicated to covering the movement ... "Rick has brought to Transportation Insight a wealth ...
(Date:3/23/2017)... As a result of diagnostic technology ... of allergic diseases, cutting edge developments in targeted ... ways in which pharmaceutical and biotech companies are ... be both a high quality meeting and a ... immunologists, research scholars and doctors. The event will ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through ... a devotional journal chronicling the writer’s path toward true communion with God. “Finding ... God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a follower ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “Vintage and Harvest ... retired minister and college Bible teacher residing in North Carolina with his wife, Anna ... have blessed them with six grandchildren. David is also the author of “Shadow and ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous ... the fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at ... her passion for writing, especially about truth and human behavior. , Published by Christian ...
(Date:3/23/2017)... ... 2017 , ... A recent report from the National Council on Teacher Quality ... report suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions ... U.S. It argues that this higher bar should be set by states, by the ...
Breaking Medicine News(10 mins):